Therapeutics

#Drug development #High Content Screening #Immunology #Therapeutics

Spotlight on Abzena’s Developability Platform

Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019. New service reduces the risk, expenditure and time required for the later stages of antibody development Abzena is showcasing its new Developability Service, enabling biotechnology and pharmaceutical companies to improve lead selection and… Read More

#News

#Academic #Analysis #Assay development optimisation & technology #Business #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Immunology #Lead discovery #Microfluidics #Pharmokinetics #Screening #Therapeutics

Carterra closes financing round for LSA platform

Carterra closes financing round for continued growth of the LSA platform for next generation antibody dscovery. Carterra has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners. The additional funding will support the continued adoption… Read More

#News

#Analysis #Drug discovery #RNA #Stem cells #Therapeutics

Advanced BioMatrix Acquires HyStem from Lineage Cell Therapeutics

Advanced BioMatrix has acquired the HyStem line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan. HyStem® kits are based on innovative thiolated hyaluronic acid technology. With HyStem®, researchers can create customizable 3D hydrogels for culturing cells whose natural environment is rich in hyaluronic acid. Read More

#News

#Drug development #Drug discovery #Drug targets #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #Therapeutics #Translational #Translational chemistry

Pathios Therapeutics closes US$8.8M Series A and appoints Stuart Hughes as CEO

The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare… Read More

#News

#Cell therapy #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Oncology #RNA #Stem cells #System biology #Therapeutics

Grey Wolf completes financing to accelerate development of ERAP2 therapies

Grey Wolf Therapeutics completes £2.5 million ($3.3 million) Series A2 financing to accelerate development of therapies targeting ERAP2. Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system. Grey Wolf Therapeutics, a drug discovery… Read More

#News

#Biochemistry #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Drug development #Drug discovery #Gene therapy #Lead discovery #RNA #Therapeutics

Enterprise Therapeutics publishes paper on novel cystic fibrosis approach

Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients. Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of… Read More

#News

#Analysis #Business #Lead discovery #Mass spectrometry / NMR #Metabolomics #Protein chemistry / Proteomics #RNA #Therapeutics

Thermo Fisher to showcase new products at Virtual ASMS Event

Thermo Fisher Scientific will provide online programming and virtual exhibits to introduce scientists to a number of new products that build on its leading Orbitrap platform and expand research applications. The company said it will showcase its newest instruments, software and workflow solutions during a company-hosted virtual event, vLC-MS.com,… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Cell therapy #Drug development #Drug discovery #Gene therapy #Immunology #Lead discovery #Oncology #Pathology #Precision medicine #RNA #Screening #Stem cells #Therapeutics

Researchers discover cell communication mechanism that drives cancer adaptation

Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies. This mechanism involves cells releasing small vesicles, known as exosomes. These contain complex mixtures of proteins,… Read More

#Cancer Research #Covid-19 #News

#Academic #Business #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Drug target for aggressive breast cancer found

A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously… Read More

#Cancer Research #News

#Academic #Business #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK government advises drug companies to stockpile in case of Brexit disruption

Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer,… Read More

#Covid-19 #News

#Business #Drug development #Drug discovery #Genetics / genomes #Immunology #Oncology #Therapeutics

Horizon Discovery licenses platform to TrueBinding for biotherapeutics development

TrueBinding, a biopharmaceutical company, has signed a set of commercial licenses for Horizon Discovery’s CHOSOURCE platform. TrueBinding will use the cGMP-compliant platform for the development and commercialisation of multiple biotherapeutic products for applications in immuno-oncology and other disease areas with great unmet medical need. Horizon’s CHOSOURCE platform includes a gene-edited… Read More

#News

#Clinical trials #Drug development #Therapeutics

Parkinson’s UK backs NRG Therapeutics’ breakthrough drug development

Parkinson’s UK has invested an additional £1 million in NRG Therapeutics mitochondrial drug development programme. This funding boost, on top of an initial £1 million investment, will support the development of a breakthrough drug with the potential to slow or halt the progression of Parkinson’s – something no… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Just-Evotec Biologics to make monoclonal antibody products for COVID-19

Image: Ani Kolleshi The US Department of Defence (DOD) has awarded Evotec’s Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19 Under the contract, Just–Evotec Biologics will design a manufacturing process for the production of Current Good… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cell therapy #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Oncology #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Merging two immunotherapies may be more effective treatment against some cancers

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of… Read More

#Cancer Research #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Precision medicine #Preclinical #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

British Patient Capital invests in life-changing biotech companies

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Cell therapy #Computational chemistry #Drug discovery #Gene therapy #Lead discovery #Oncology #RNA #Stem cells #Therapeutics

Immune system could be trained to spot drug-resistant cancers

Aggressive cancers could be treated with immunotherapies that direct the immune system to kill cancer cells with specific drug resistance-causing mutations, a major new study suggests. Drug resistance mutations which restore activity of the BRCA1 or BRCA2 genes as a way of avoiding the effects of drug treatment… Read More

#Cancer Research #Covid-19 #News